N-formylphenylacetamide | 4252-32-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-formylphenylacetamide
• 英文别名: N-formyl-2-phenyl-acetamide；N-Formyl-phenylacetamid；N-formyl-2-phenylacetamide
• CAS: 4252-32-8
• 化学式: C₉H₉NO₂
• mdl: MFCD00157627
• 分子量: 163.176
• InChiKey: LLXPNYVWDXGYFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-formylphenylacetamide 、 (2,3-二氯苯基)肼 在 溶剂黄146 作用下， 以28%的产率得到5-benzyl-1-(2,3-dichlorophenyl)-1H-1,2,4-triazole
  参考文献：
  名称：

  Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists

  摘要：

  Structure-activity relationship (SAR) studies were conducted around early tetrazole-based leads 3 and 4. Replacements for the tetrazole core were investigated and the pendant benzyl substitution was reoptimized with a triazole isostere. Triazole-based P2X(7) antagonists were identified with similar potency to the lead compound 4 but with improved physiochemical properties. Compound 12 was active in a rat model of neuropathic pain. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.075
• 作为产物：
  描述：

  2-苯乙酰胺 在 水 、 苯甲酰氯 作用下， 生成 N-formylphenylacetamide
  参考文献：
  名称：

  A Preparation of Aroyl and Acyl Formamidinium Salts

  摘要：

  DOI：

  10.1021/jo01019a523

文献信息

• New Synthetic Method of Imides through Oxidative Photodecarboxylation Reaction of<i>N</i>-Protected α-Amino Acids with FSM-16
  作者：Akichika Itoh、Tomohiro Kodama、Shinji Inagaki、Yukio Masaki

  DOI：10.1246/cl.2000.542

  日期：2000.5

  FSM-16, a mesoporous silica, was found to promote the oxidative photodecarboxylation of N-acyl-protected α-amino acids in hexane to afford the corresponding imides.

  FSM-16 是一种介孔二氧化硅，被发现可促进 N-酰基保护的 α-氨基酸在己烷中的氧化光脱羧，得到相应的酰亚胺。
• Oxidative Photo-Decarboxylation in the Presence of Mesoporous Silicas
  作者：Akichika Itoh、Tomohiro Kodama、Yukio Masaki、Shinji Inagaki

  DOI：10.1248/cpb.54.1571

  日期：——

  FSM-16, a mesoporous silica, was found to catalyze oxidative photo-decarboxylation of α-hydroxy carboxylic acid, phenyl acetic acid derivatives and N-acyl-protected α-amino acids to afford the corresponding carbonyl compounds. Furthermore, FSM-16 proved to be re-usable by re-calcination at 450 °C after the reaction.

  FSM-16，一种介孔硅，被发现能够催化α-羟基羧酸、苯乙酸衍生物和N-酰基保护的α-氨基酸的氧化光脱羧反应，生成相应的羰基化合物。此外，FSM-16通过在反应后在450°C下重新煅烧证明是可重复使用的。
• 2-AMINOPYRIDINE KINASE INHIBITORS
  申请人：Steinig Arno G.

  公开号：US20090197862A1

  公开（公告）日：2009-08-06

  2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

  具有Formula I结构的2-氨基吡啶化合物，以及这些化合物的药用可接受的盐。Formula I的化合物抑制动物（包括人类）中的酪氨酸激酶酶活性，并可用于治疗和/或预防各种疾病和病况。特别地，本文披露的化合物是激酶抑制剂，特别是但不限于KDR、Tie-2、Flt3、FGFR3、Ab1、Aurora A、c-Src、IGF-1R、ALK、c-MET、RON、PAK1、PAK2和TAK1，并可用于治疗增生性疾病，如但不限于癌症。本发明还涉及一种包含Formula I化合物的药物组合物，或其药用可接受的盐，以及药用可接受的载体的药物组合物。本发明还涉及一种通过向患有由蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
• P2X7 receptor antagonists and methods of use
  申请人：Carroll A. William

  公开号：US20070105842A1

  公开（公告）日：2007-05-10

  The invention is directed to compounds that are P2X 7 antagonist and have the formula (I) or (II) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein R 1 , R 2 , and R 3 are defined in the specification. The invention is also directed to a method of selectively inhibiting P2X 7 activity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), (IV) or (V) wherein R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are defined in the specification.

  这项发明涉及具有化学式(I)或(II)的P2X7拮抗剂化合物，或其药学上可接受的盐、前药、前药的盐或二者的组合，其中R1、R2和R3在规范中有定义。该发明还涉及一种选择性抑制P2X7活性的方法，包括向需要此类治疗的患者施用化合物的治疗有效量，其化学式为(III)、(IV)或(V)，其中R6、R7、R8、R9、R10和R11在规范中有定义。
• Amine derivative compounds
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030078426A1

  公开（公告）日：2003-04-24

  An amine compound of the formula (I): 1 wherein R 1 represents an optionally substituted carbamoyl group, etc., R 2 represents a hydrogen atom, etc., R 3 represents a C 1 -C 10 alkyl group etc., W 1 , W 2 and W 3 are the same or different and each represent a single bond or a C 1 -C 8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a ═CH— group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

  化合物的结构式（I）如下：其中R1代表可选择取代的氨基甲酰基团，R2代表氢原子等，R3代表C1-C10烷基等，W1、W2和W3相同或不同，每个代表单键或C1-C8烷基链，X、Y和Q代表硫原子等，Z代表═CH—基团等，Ar代表苯环等，L代表氢原子等，或其药理学上可接受的盐。这些化合物在治疗和/或预防糖尿病、高脂血症、动脉硬化、癌症等疾病方面具有用处。